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Retinoic Acid Hydroxylase Inhibitors as a Novel Therapy for Alzheimer’s Disease
Faculty Mentor: Philippe Diaz
Alzheimer’s Disease (AD) is one of the most prevalent neurodegenerative diseases
afflicting the modern world. As no cure for AD has yet been discovered we sought to
explore a potential treatment option based on the inhibition of retinoic acid (RA)
metabolism, the active metabolite of vitamin A. Beta-amyloid plaques form in the
brain and decrease cognitive function in AD patients. In a recent preclinical study
RA was shown to decrease these plaques and rescue memory deficits in an
Alzheimer’s mouse modeli. One key limitation is that when RA is administered to
humans it induces its own breakdown, making it less effective for long-term
treatment. The proteins mediating RA breakdown are named CYP26. Of the CYP26
enzymes identified as clearing RA, CYP26B1 appears to be the predominant brain
isoform. We hypothesize that the inhibition of CYP26 would cause an increase in the
amount of RA concentration in the brain, thereby improving AD patient outcomes.
Using two behavioral maze tests, the Morris Water Maze (MWM) and Y maze, we
assessed cognitive function based on how quickly the mice maneuvered the mazes.
We have begun preclinical testing of the prototypical CYP26 inhibitor in Alzheimer’s
mice relative to wild type (WT) litter-mates. A MWM measure of latency to the end
of the maze showed a discrepancy between the performances of AD and WT mice,
with the AD mice exhibiting a considerable cognitive deficit. The mice then received
8 weeks of treatment with the first selected CYP26 inhibitor NMP300 (3 times per
week at 10 mg/kg i.p.). A follow-up MWM was performed and no significant reversal
of cognitive deficits in AD mice was detected. A more recent MWM study of 31
treated AD mice is currently being analyzed and shows promising similarities

between AD and WT latencies. Furthermore, the stained brain tissues of these mice
show a decrease in Beta-Amyloid plaques in AD mice that have received treatment.
These results provide a strong foundation from which to further explore the use of
these CYP26 inhibitors in treating AD.
Introduction
The Role of Retinoic Acid in the Body
Retinoic acid (RA) isomersii, the metabolites of vitamin A, are important
endogenous signaling molecules critical for a number of biological processesiii
including cell differentiationiv and neural plasticityv. RA isomers are involved in
maintaining homeostasis of various tissues, including the brainvi. The biological
activity of retinoids is largely mediated by their binding to the retinoic acid
receptors (RAR)vii and the retinoid X receptors (RXR)viii located in the cell nucleus.
RA and synthetic retinoids have been suggested to have therapeutic uses
in neurodegenerative disordersix. However, the therapeutic chronic uses of
currently available synthetic retinoids are limited due to potential side effects, such
as retinoic acid syndromex.
Examining CYP26 Inhibitors as Treatment for Alzheimer’s Disease
The clearance of RA is predominantly mediated by cytochrome P450 family
26 enzymes (CYP26)xi. The CYP26 family has three isoforms: CYP26A1, CYP26B1
and CYP26C1xii. While CYP26A1 is the human liver atRA hydroxylase, CYP26B1 is
predicted to be responsible for atRA metabolism in extrahepatic tissues and
CYP26C1 is responsible for 9-cis metabolismxiii. Of the RA clearing enzymes,
CYP26B1 appears to be the predominant brain isoform, whereas CYP26A1 seems to
function in tissues with high metabolic capacity such as the liverxiv. When atRA is
administered to humans, it induces its own metabolism likely via CYP26, which
leads to resistance to RA treatment. Hence, we hypothesize that selective
inhibition of CYP26B1 in the brain will increase concentrations of neuronal
RA and provide a therapeutic advantage in AD. Inhibition of CYP26A1 would

increase circulating RA concentrations but will have a smaller effect on brain RA
concentrations than a CYP26B1 inhibitor and will result in systemic side effects.
Methods
Transgenic mice and CYP26 Inhibitor Treatment
All procedures were performed in accordance with the University of Montana
Institutional Animal Care and Use Committee. A transgenic (Tg) 5-Familial
Alzheimer’s disease mouse line was acquired from Jackson Laboratories in Bar
Harbor, Maine. The original mice were crossed and F2 and F3 generations were
genotyped using polymerase chain reaction (PCR) to establish the presence of the
AD genes. This was done using primers #123513562, #123513561, #123513564
and #123513563. Transgenic mice were further crossed to establish a colony and
each generation was subsequently genotyped. Transgenic and wild type (WT) mice
were divided into groups for experimental use and were treated with different
dosages of the CYP26 inhibitor, NMP308. The treatment was continued for the
duration of 13 weeks, with three treatments per week. This exceeded the 8-week
treatment period but an exception was made due to time constraints. The drug was
introduced through intraperitoneal injections. The mice were weighed once a week
during the first eight-weeks of treatment to ensure that no dramatic weight
fluctuations occurred due to drug toxicity.
Morris Water Maze Protocol
After treatment the mice performed a Morris Water Maze (MWM) in order to test
cognitive function. This test examines spatial learning and memory in micexv. The
MWM consisted of a 1.76 ft tall and 4 ft across round galvanized steel tank with the
edges and walls painted matte white to reduce glare. A platform made of a section of
10 cm wide PVC pipe, mounted on a stabilizing block with weights was covered with
mesh and placed in the tank to act as a landing site for the animals. Non-toxic white
tempera paint was added to the water to make it opaque and distal cues were
placed 3 feet from the edge of the tank. The tank was divided into four quadrants
with AnyMaze tracking software and the platform was left in the same quadrant

throughout the entire test. On the first day of the MWM a colleague determined
treatment groups and the mice were placed alone in empty cages before being
observed and weighed. A probe trial was then performed on Day 0 of the
experiment. First a small flag was attached to the platform and the tank was filled
with 22.5 cm of water at 20-22˚C. The first mouse was placed in the tank at a
predetermined location and the tracking software on the computer was started. The
mouse was allowed to swim for 60 seconds and if it did not locate the platform it
was placed there and allowed to rest for 30 seconds. Then, the mouse was placed in
its empty cage underneath the heat lamp and allowed it to remain for the trials of
two more mice to prevent hypothermia. During days one through three of the MWM
the platform was placed in the same location and the mice performed four 60second trials, being placed in the tank at four different starting locations, facing the
wall each time. If the mouse did not find the platform, it was guided there and
allowed it to rest for 30 seconds. As with the probe trial, the mouse was allowed to
sit under the heat lamp for two more trials. Day five was a rest day and a final probe
was performed on day six to assess memory function in the mice. During this final
probe trial the platform was removed and all other conditions were kept constant.
The mouse was placed in the tank facing the wall and allowed to explore for 60
seconds. As in the first probe trial, each mouse was allowed one session in the tank
before being removed to its cage.
This protocol was modified from (Vorhees and Williams, 2006).

Y Maze Test
A prescreen was performed the day before the Y-maze. This included observing the
mouse in the home cage, assessing eye, ear and whisker reflexes and weighing the
mouse. The mice were individually placed in empty cages and randomized by a
colleague. The test was performed the following day. A mouse was placed in the
start arm of the maze and the computer software was started. The mouse was
allowed to roam for five minute, exploring the maze at will. The number of
alternations to various arms was recorded during the five-minute trial, and

provided the basis of the behavioral analysis. The mouse was then removed, the
maze was cleaned with 10% ethanol, and the next mouse was placed in the maze.
The results of this test were determined by the percentage of alternations made by
the mouse. A normal WT mouse will theoretically travel to each arm of the maze in
turn, alternating evenly between all of them. A mouse with a functioning memory is
unlikely to travel to the same arm twice in a row. Consequently, the AD mice are
expected to return to the same arm multiple times in a row because they lack the
memory of having recently visited said arm.
Perfusion and Histology
After the Y-maze and MWM behavior tests were performed the mice were
anesthetized with Isoflurane in an anesthetizing box and then perfused and with
PBS and 4% paraformaldehyde. The brains were soaked for 24 hours in PBS, then
24 hours in 4% paraformaldehyde and then were placed in 70% ethanol until they
could be embedded in paraffin. Once the tissue was embedded the paraffin blocks
were vertically sectioned with a microtome setting of 7 microns. The sections were
floated on a warm water bath and mounted on SuperFrost glass slides. The sections
were collected at intervals of 8. They were then deparaffinized and hydrated in
distilled water. The slides were stained for 12 minutes in Congo Red solution, rinsed
and differentiated in an alkaline alcohol solution. The slides were rinsed in tap
water for 5 minutes, dehydrated with 95% and 100% alcohol, cleared in xylene and
mounted with a resinous mounting medium. Following this procedure the brain
sections were imaged on a confocal microscope with the 10x objective.
Statistical Analysis
Analyses were performed using Microsoft Excel. Data is shown with a mean +/SEM.
Results
Behavioral Tests

To examine the effects of the CYP26 inhibitor NMP308 in the brains of AD mice we
performed Y-maze and Morris Water Maze (MWM) behavioral tests. Four groups of
mice, age 10 months, were injected with the drug for 13 weeks. A group of
Transgenic (Tg) mice (n=7) and a group of WT mice (n=9) were injected with 10
mg/kg of the drug. Another group of Tg (n=6) and a group of WT (n=9) mice were
injected with 20 mg/kg doses. The MWM was executed after treatment and allowed
us to determine whether the CYP26 inhibitor was affecting cognitive function in the
mice. This was accomplished by comparing the groups to one another and to a
previously tested untreated group of mice. The most indicative measure of cognitive
function in the MWM is latency to platform (see methods). The latencies of mice (Fig
1.) to the MWM platform were within a range of statistical insignificance (t-test >
.05) between the four groups of mice.
We then perfused the mice and prepared stains for imaging (see methods). The
Congo Red stain highlights the Beta-amyloid plaques within the brain tissue of the
mice. It can be seen in Figure 2 that WT mice have no plaques whatsoever. The Tg
mice that were treated with the 20 mg/kg dosage of the drug have fewer plaques
than those treated with the 10 mg/kg dosage. A method to quantify the number of
plaques in each tissue sample has not yet been determined

Discussion
Through the course of this study we have gained insight into the accuracy and
effectiveness of the MWM behavioral test as well as into the effects of the CYP26
inhibitor on Beta-amyloid plaques in the brain tissue.
Latency to Platform as Measure of Cognitive Function in MWM
Figure 1 and the accompanying statistical tests indicate that there is no significant
difference in the performances of WT and Tg mice in the MWM. Nor is there a
discrepancy in the performance of the two different treatment groups (20 mg/kg
versus 10 mg/kg) Tg mice. This could indicate that the cognitive function of the Tg

mice is improving and causing them to perform more like their WT litter-mates.
However, MWM tests performed on previous groups of WT and Tg mice have shown
a similar lack of statistical significance (t-test > .05) between WT and Tg latencies in
untreated mice. This is unexpected, as WT mice should show significantly better
cognitive function when compared to mice with advanced Alzheimer’s disease.
Because these initial MWM tests did not provide the expected results it is difficult to
trust the most recent test displayed in Figure 1. Therefore, we have determined to
place little faith in the MWM behavioral test as an indicator of the effectiveness of
our drug and instead turn to histology for answers.
Beta-Amyloid Plaques in Congo Red Stained Brain Tissue
The Congo Red stain used in the histology process is one that indicates BetaAmyloid plaques in the brain. We stained Tg tissue that was vehicle treated (Figure
3), tissue from mice that were treated with 10 mg/kg doses (Figure 4) and 20
mg/kg doses of NMP308 (Figure 5). Although no method of quantifying the plaques
has yet been determined, we used visual analysis to conclude that mice treated with
20 mg/kg doses for 13 weeks showed fewer plaques in their brain tissue than mice
that were untreated or treated with the lower dosage. There is not a noticeable
difference between the vehicle treated and 10 mg/kg treated Tg mice, possibly
because the 10 mg/kg dose was not concentrated enough to affect the plaques. The
decrease of plaques among 20 mg/kg treated mice seems to be a trend consistent
between all samples. To further determine the implications of the histology slides a
quantification method will need to be determined to accurately gauge the number of
plaques in each tissue sample and draw further conclusions.

Implications for Alzheimer’s Disease Treatment
Through this study we have gained valuable information regarding Alzheimer’s
disease mouse models as well as the effects of our CYP26 inhibition drug on said
mice. Beta-amyloid plaques are strongly associated with the development of
Alzheimer’s disease. Therefore, the measurement of these plaques is an indicator of

whether or not a mouse has AD and whether the drug therapy is decreasing the
effects of the disease. Future steps for this study include developing a Beta-amyloid
plaque measurement technique and performing tests with varying concentrations of
our drug to ascertain effective dosing for future studies.
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Figure 1. Latency to Platform of WT and Tg mice from 20 mg/kg and 10 mg/kg
NMP308 Treatment Groups. Mice performed four 60 second trials over the course
of three days, during which they are expected to learn the location of the
underwater platform aka their “escape route”. Theoretically the mice should reach
the platform with increasing speed each day as their knowledge of the maze
increases. It is expected that WT mice will reach the platform more quickly than Tg
mice, which is not the case here; all four groups of mice in this test performed
similarly enough that their results showed no statistically significant difference (ttest > 0.05).

Figure 2. NMP308 10 mg/kg Treated WT Mouse. This mouse was treated with a
10 mg/kg dosage of the CYP26 inhibitor over the course of 13 weeks. No bright red
dots (representing Beta-amyloid plaques) are present in this tissue, which is to be
expected in any WT mouse. The treatment was not expected to have an effect on the
WT tissue but was administered as a control.

Figure 3. Vehicle Treated Tg Mouse. This mouse was treated for 13 weeks with
the vehicle that is used to administer the CYP26 inhibitor. In theory this mouse
should have felt no effects since the vehicle is intended to be merely a means of
transportation and not to have a tangible effect. Therefore, the plaques in this
mouse should be the same as those in an untreated AD mouse.

Figure 4. NMP308 10 mg/kg Tg Mouse. This animal was treated with a dosage of
10 mg/kg for the course of 13 weeks. Though we have not been able to quantify the
plaques present, we can see by comparison that this tissue seems to have slightly
fewer plaques than the vehicle treated Tg mouse, although not substantially so.

Figure 5. NMP308 20 mg/kg Treated Tg Mouse. This Tg mouse was treated with
20 mg/kg doses of CYP26 inhibitor for 13 weeks. Again, there is no quantification

method for comparing the plaques but this mouse appears to have significantly
fewer plaques than the vehicle treated Tg shown in Figure 3. This tissue also has
fewer plaques than are present in the 10 mg/kg treated mouse shown in Figure 4.
This suggests that the higher dosage has a stronger effect in clearing Beta-Amyloid
plaques from the brain.
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